Novo Nordisk A/S Common Stock (NVO)

Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.

Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk.

The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.

This beaten-down drugmaker is well positioned to turn things around.

Now may be the time to invest in drug companies, as they just slipped the tariff noose.

Healthcare stocks haven't been very popular this year. It could be a great time to buy some of the industry's leaders.

Novo Nordisk exemplifies affordable growth, combining strong revenue and earnings expansion with a reasonable valuation and top-tier profitability.

The fallen pharma giant could make a big comeback in 2026.

Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.

Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in understanding the pharmacokinetic profile of this potential therapy. While this marks a technical advancement in drug development, the news

Novo Nordisk to buy Akero Therapeutics for up to $5.2 billion, adding EFX, a late-stage MASH treatment candidate, to its metabolic disease portfolio.

The deal follows Roche's plan to buy 89bio, another MASH-focused biotech company.

Novo Nordisk is set to acquire the firm, and Akero’s shareholders will receive $54 per share in cash at closing in addition to a contingent value right.

Novo Nordisk has cut dozens of jobs at its Clayton, North Carolina site, part of a global restructuring as it faces slowing weight-loss drug sales.

After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.

Skye Bioscience'a trial showed nimacimab alone missed goals, while a combo with Novo Nordisk's drug delivered stronger weight loss results.

The market is sleeping on these stocks, but you don't have to.

Anthropic, a leading artificial intelligence research company, is making significant strides in embedding its powerful Claude AI into the fabric of daily applications and enterprise workflows. With a strategic focus on safety, ethical development, and robust integration protocols, Claude is rapidly transforming from a sophisticated chatbot into an indispensable, context-aware AI collaborator across a myriad [...]

Copenhagen, Denmark – October 2, 2025 – Shares of Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) experienced a significant surge yesterday, October 1, 2025, following a pivotal upgrade from HSBC. The financial institution elevated Novo Nordisk's rating from "Hold" to "Buy," triggering a robust 6.6% climb in the company's stock price.